

# Early detection of Alzheimer's: Modalities and Methods

**M. Monisha<sup>1</sup>, K. M. Harshitha<sup>2</sup>, N. H. Dhanalakshmi<sup>3</sup>, Kokatam Sai Prakash Reddy<sup>4</sup>, C. R. Nagarathna<sup>5</sup>, M. Kusuma<sup>6</sup>**

<sup>1,2,3,4</sup>Department of Information and Science, Dayananda Sagar Academy of Technology and Management, Visvesvaraya Technological University, Bangalore, India

<sup>5</sup>Assistant Professor, Visvesvaraya Technological University, Bangalore, India

<sup>6</sup>Professor, Visvesvaraya Technological University, Bangalore, India

**E-mail:** <sup>1</sup>monishasmekala@gmail.com, <sup>2</sup>harshithakmurali@gmail.com, <sup>3</sup>dhanalakshminh.work@gmail.com,

<sup>4</sup>saiprakash2610@gmail.com, <sup>5</sup>nagarathna.binu@gmail.com, <sup>6</sup>kusumalak@gmail.com

## Abstract

Alzheimer's disease belongs to the group of neurodegenerative diseases and is considered as one of the most destructive and severe diseases of the human nervous system. There is presently no quick and cost-effective method for routinely screening individuals of age 65 and older for Alzheimer's disease, the most prevalent type of neurodegenerative dementia. Over 5.2 million Americans already suffer from this condition, with the number anticipated to rise to 7.7 million by 2030. This paper discusses how the use of Machine learning concepts has upgraded the detection of Alzheimer's disease in the early stage.

**Keywords:** Alzheimer's disease, Cognitive Normal, predictive testing, Positron emission tomography, Support vector machine, Machine learning

## 1. Introduction

Alzheimer's disease is a neurological disease that makes the brain shrink and destroys the brain cells. Alzheimer's is a type of common dementia that impacts memory, and thinking skills, and patients lose the ability to implement simple everyday activities or function independently.

Alzheimer's disease generally starts slowly and gradually worsens over time. As most of people's common initial symptom is trouble in recalling recent activities. As the condition advances the person will develop critical memory impairment and will lose the ability to perform everyday activities. Alzheimer's disease has no treatment to cure it. Even after the diagnosis, a person can only live up to 4 to 8 years on average.

Alzheimer's disease generally progresses slowly in three stages: CN stage, MCI stage and AD stage i.e., early, middle and late stages. CN stage is the initial stage, where a person will have symptom to forget minor things like he or she has kept a book on a table, but the person is facing difficulty in recalling it after a few minutes or the person facing difficulty because of forgetting that was just read. MCI stage is the longest stage and can last for many years. The symptoms in this stage is, where the person may confuse words, mood swings such as getting frustrated or angry and may act in unexpected ways. Destruction of brain cells can also make it difficult for the person to express their thoughts and implement routine tasks. The final stage of the disease is the AD stage which has severe symptoms. The patient with MCI will progress to Alzheimer's disease at a rate of 15% per year. The symptoms of AD stage are individuals lose the tendency to respond to their environment, to convey or maintain a conversation and eventually to control movement.

Hopeful results were seen in the classification of Alzheimer's disease (AD) using Machine Learning methods, but combination of high accuracy and short processing time is required for successful application in clinical settings. Our Objective is to Build and analyse models for early prediction of Alzheimer's disease (AD). In this study, Alzheimer's disease will be analysed. The problem is how to diagnose it at the earliest possible stage before specific symptoms begin to appear. The main idea is to build an intelligent system that will be able to answer, based on certain biomarkers from the subject, whether the disease is present or not.


## **2. Modalities**

### **2.1 PET Scan**

Positron Emission Tomography (PET)[13] along with other imaging techniques are used to let out several details of dementia physiology, such as tau and amyloid accumulation in the brain, neuron inflammation, and information about irregular metabolism in dementia patients. One of the methods is imaging with PET by using radioligands that bind to amyloid-beta ( $A\beta$ ), in particular  $[^{11}C]$  PiB compound i.e., Pittsburgh B compound are used to determine the amount of brain amyloid burden and hence the pre-symptomatic stages of the Alzheimer's disease.

Although few studies have proved good sensitivity in predicting AD at pre-symptomatic stages using PET scans, an absolute threshold for shaping the test positivity is

not defined. Moreover, PET scan is an expensive method, so standardizing the process is important. However, PET scan has limited advantages because it is costly and it is peculiar for centres [2]. In figure 1, the white matter is the growth of  $[^{11}\text{C}]$  PiB compound in a CorticoBasal Syndrome (CBS) patient ((a.) age 75) and immense cortical in an AD patient [13].



**Figure 1.**  $[^{11}\text{C}]$  PiB PET scan images

## 2.2 MRI Scan

Deep learning, a concept in machine learning has won a lot of advantages over traditional machine learning. Especially when using a high-dimensional and complex data for training the model. The same feature of deep learning has been used for early detection of Alzheimer's disease and gained attention. Deep learning papers on Alzheimer's disease were found and out of 16 papers, combination of deep learning and usual machine learning concepts were used in 4 papers and 12 were about using deep learning concepts alone. After studying the above 16 papers, it could be concluded that 83.7% accuracy was achieved in prediction when the combination was used and about 84.2% accuracy was achieved in prediction of MCI conversion [14]. Deep learning which is a part of machine learning uses raw neuro-imaging data [14]. Neuro-imaging data means a data that is both complex and high-dimensional (very large). But detecting Alzheimer's disease through MRI scan images is possible only the amyloid is already accumulated around brain cells in the AD stage. And at this stage it's too late to know about the disease.

## 2.3 Blood Plasma

So far, only amyloid biomarkers were used to detect Alzheimer's disease. But by using non-amyloid biomarkers Alzheimer's disease can be detected in early stages. Using amyloid biomarkers will only give bounded information about progress and are inefficient in detecting the disease before remarkable accumulation of amyloid around the brain cells. By using blood plasma Alzheimer's disease can be detected in early stages with the help of few non-amyloid proteins present in plasma, thrifty and convenient as well [15].

## 3. Existing Methods

While modern clinical, cerebrospinal fluid and neuroimaging studies are highly accurate in diagnosing Alzheimer's disease, these methods are prohibitively expensive for extensive screening. Furthermore, these technology and specialized services are not voluntarily available to everyone, such as rural seniors and ethnic minorities, limiting their use as AD screeners. A blood-based test, on the other hand, would give a speedy and thrifty way of screening for Alzheimer's disease at the high-population level, therefore expanding worldwide access to care [6]. As a part of a multi-stage approach, this sort of blood test would be an absolute initial screening tool, with advanced neuroimaging, clinical, and/or cerebrospinal fluid investigations available for screen-positive patients. On top of this, a precise and simple screen would result in a thrifty method of screening for clinical trials. Molecular biomarkers have traditionally focused on single molecules, but as proteomic, genomic, and metabolomic technology advances, it is becoming more viable to construct classifiers based on a variety of complicated disease signatures [6].

While the hunt for blood-based non-amyloid biomarkers of Alzheimer's disease has been mainly futile for years, substantial progress has lately been made. Ray et al. looked at a variety of non-amyloid plasma-based proteins and came up with a model of algorithm that correctly categorized AD and predicted the disease progress between mild cognitive impairment and AD. Very recently, Booij et al. and Rye et al. completed a few studies using arrays of gene expression and identified that overall diagnosis accuracy ranged from 74% to 92%. A serum-based algorithm was developed based on the Texas Alzheimer's Research Consortium's longitudinal cohort that had good diagnostic accuracy, properly categorizing 95 percent of AD patients and controls [6]. There is a conspicuous requirement for precise and powerful analytic and prognostic biomarkers for Alzheimer's sickness, and there has been a monstrous ascent in endeavors to track down such markers as of late. It has recently been

suggested that the ideal biomarkers would be gotten from fringe blood because of its impressive advantages. Fringe blood might be drawn at any center (or during an in-home visit), however, most facilities can't do lumbar cuts. Progressed neuroimaging strategies are likewise regularly just accessible in large clinical offices in thickly populated regions. While practically all patients are prepared to persevere through venepuncture, less seasoned people agree to lumbar cut, and many can't go through neuroimaging for an assortment of reasons [4].

**Table 1.** List of available datasets for Alzheimer's disease prediction

| S.No | Dataset                                         | Description                                                                                                                                                                                                                        |
|------|-------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1    | Kaggle [20]                                     | Alzheimer's dataset. The data is manually collected and consists of MRI images.                                                                                                                                                    |
| 2    | ADNI [21]                                       | Alzheimer's Disease Neuroimaging Initiative began in 2004. The main goal of ADNI is to detect AD at the earliest possible stage. The data is available in many types like clinical, genetic, MRI image, PET image and biospecimen. |
| 3    | Alzheimer's Disease and Healthy Aging Data [22] | Published by Centers for Disease Control and Prevention, USA on November 20, 2020. The data is available in csv, JSON, RDF, XML formats.                                                                                           |

Biomarkers can recognize endophenotypes inside AD populaces connected with specific sickness pathways, as well as give more open, fast, cost-and time-compelling methods for assessment. Designated medicines custom fitted to endophenotype status may be investigated once the endophenotype status is not set in stone [4].

Plasma cholesterol, for instance, is an important biomarker in the treatment of coronary conduit illness since it can recognize a subgroup of people whose atherosclerosis is pathogenically associated with hypercholesterolemia. Plasma cholesterol levels can be utilized to survey the viability of reductase inhibitor treatment. It would be a huge advance forward in this area in case this calculated structure could be meant AD. The revelation of a favorable to incendiary endophenotype of Alzheimer's infection could prompt designated therapeutics for a subgroup of patients, with those with an over-articulation of the supportive

of provocative biomarker profile profiting from mitigating drugs and those with an under-articulation profiting from calming drugs [4].

Enormous scope proteomic profiling of the blood has been broadly taken on to concentrate on cardiovascular sicknesses and maturing, bringing about the ID of novel biomarkers and giving organic comments to illness stages, on account of ongoing advances in ultrasensitive and high-throughput protein estimation innovations. Thus, the vicinity augmentation measure procedure was utilized to inspect the protein profiles of AD plasma in this examination. After evaluating 1160 plasma proteins, it was identified that 429 plasma proteins were deregulated in patients with AD in a Hong Kong Chinese AD accomplice comprising of 106 AD patients and 74 solid controls for whom all the segment information, cerebrum locale volumes, intellectual measures, and plasma biomarker levels were cordial. Likewise, a 19-protein based biomarker board was found that addresses the plasma proteomic mark that belong to Alzheimer's sickness and affirmed its brilliant exactness for distinguishing AD and related endophenotypes in a different example [5].

Besides, it was observed that specific proteins in plasma are deregulated at various periods of Alzheimer's sickness. Subsequently, fostering a total profile of the AD plasma proteome and a superior presentation plasma biomarker board for AD was done, laying the preparation for the advancement of a blood-based test for AD screening and arranging [5].

Although there is no remedy for Alzheimer's infection, analysts are striving to find novel treatment techniques that may help slow or stop the sickness. Such medicines are aimed at patients in the beginning phases of the illness before patients have experienced serious cell harm when treatment is bound to be helpful. The utilization of perceived biomarkers, for example, those dependent on A $\beta$  in the cerebrospinal fluid and sub-atomic imaging of cerebrum amyloidal affidavit utilizing positron outflow tomography, is encouraged to help early determination [15].

Regardless of progressions in the production of amyloidal biomarkers and tests for early Alzheimer's infection identification, developers face two key difficulties. Amyloid-based biomarkers just give a restricted measure of data in regards to disease etiology and pathways. Besides, testing dependent on these biomarkers can't identify those in danger of Alzheimer's infection before there is a crucial amyloid-beta collection in the mind. There is a requirement for the biomarkers that are capable of distinguishing natural cycles that happen before amyloid-beta development in the mind during infection movement. Such biomarkers

may assist specialists with bettering comprehending the condition, just as distinguish individuals in the beginning phases of the infection and make novel medicines [15].

A study was also done with a hybrid model, a combination of VGG19 and other additional layers along with a Convolutional Neural Network for detecting and classifying various stages of AD [16]. High throughput tests have as of late become more practical on account of the presentation of board-based proteomics. SOMA scan, for instance, accommodates concurrent estimation of 41000 proteins and has effectively been utilized in Alzheimer's exploration. This technique still can't seem to be utilized to find blood-based biomarkers for AD-related qualities in symptomless individuals. Although most blood protein-based biomarker studies have used gatherings of individuals, a single exploration of APOA1 blood DNA methylation and protein level utilized 24 twin sets that were dissonant in verbose memory work. Dissonant verbose memory has been connected to two APOA1 CpG districts. Nonetheless, in light of the little example size accessible, the APOA1 protein level was not shown to vary across conflicting twins [12].

**Table 2.** The summarisation of the referred papers

| S. No. | Author                              | Year | Dataset                     | Features                                  | Method              | Accuracy |
|--------|-------------------------------------|------|-----------------------------|-------------------------------------------|---------------------|----------|
| [1]    | Elisabeth H. Thijssen <i>et al.</i> | 2020 | ARTFL                       | Plasma phosphorylated tau181              | -                   | -        |
| [2]    | Alessandro Rabbito <i>et al.</i>    | 2020 | -                           | Biomarkers                                | -                   | -        |
| [3]    | LinLiu                              | 2020 | Dem@Car e project           | The spectrogram features from speech data | Logistic regression | -        |
| [4]    | Sid E. O'Bryant <i>et al.</i>       | 2011 | TARC                        | A Multiplex Serum Protein-based marker    | Random Forest       | 90%      |
| [5]    | Yuanbing Jiang <i>et al.</i>        | 2021 | Hong Kong Chinese AD Cohort | Plasma Biomarkers                         | Linear Regression   | -        |

|      |                                    |      |                                           |                                         |                              |        |
|------|------------------------------------|------|-------------------------------------------|-----------------------------------------|------------------------------|--------|
| [6]  | Sid E. O'Bryant <i>et al.</i>      | 2011 | TARC                                      | 30 Serum protein markers                | Linear Regression            | 89%    |
| [7]  | Sid E. O'Bryant <i>et al.</i>      | 2011 | TARC, ADNI                                | Protein Biomarkers                      | Random Forest                | 70%    |
| [8]  | Jinny Claire Lee <i>et al.</i>     | 2019 | -                                         | Fluid Biomarkers                        | -                            | -      |
| [9]  | Henrik Zetterberg <i>et al.</i>    | 2019 | -                                         | Blood-based Molecular Biomarkers        | -                            | -      |
| [10] | Nicholas J. Ashton <i>et al.</i>   | 2019 | AIBL<br>KARVIA<br>H                       | Plasma Proteins                         | Support Vector Machine (SVM) | 81%    |
| [11] | A. Hye <i>et al.</i>               | 2006 | 2- DGE                                    | Proteome-based plasma biomarkers        | Support Vector Machine (SVM) | 56%    |
| [12] | SJ Kiddle <i>et al.</i>            | 2015 | TwinsUK<br>AddNeuro Med (ANM)<br>SOMAscan | Plasma protein Biomarkers               | -                            | -      |
| [17] | Martin Gomez Ravetti <i>et al.</i> | 2008 | -                                         | 5-Protein Biomarker Molecular Signature | Random Forest                | 92%    |
| [18] | Steven John Kiddle <i>et al.</i>   | 2012 | ADNI                                      | Brain Amyloid Burden                    | Multiple Linear Regression   | 91.8%  |
| [19] | Hamed TaheriGorji <i>et al.</i>    | 2020 | TADPOL E                                  | Biomarkers                              | AdaBoost                     | 92.86% |

#### 4. Gap Identification

- In Hamed's study [3], the results demonstrate that selecting the features conventionally or conventional methods is not always reliable and may discount some biomarkers with high importance during the feature selection process.

- As for Zetterberg, H., & Burnham, S. C. [9], instruments for quantifying blood biomarkers become more receptive and sensitive, hence the understanding and implementation of standardized procedures for sample processing and analysis are increased, the field moves closer to the search for blood biomarkers in AD. Thus, shows promising results, but the protocol is very hard to follow and complicated to draw strong conclusions.
- In the study made by James Hall and Rachelle Dooby, there is no rapid thrifty means for providing routine screening of adults age 65 years and above for Alzheimer's disease detection.
- According to Chime S. Eke et al [15], the successful development of amyloid-based biomarkers and a test for Alzheimer's disease represents an important milestone in AD diagnosis. However, two major limitations remain. Limited Information about the disease and Identifying individuals with the disease in its late stages.

## 5. Conclusion

Hence, a careful study is made to understand the necessary parameters that have to be well scrutinized for the early detection of AD. The two useful methods in estimating levels of brain amyloid burden are PET (expensive and limited to specialized centres) and cerebrospinal fluid (patient feels discomfort and won't be present in primary health care centres). Therefore, the two existing methods are inefficient, hence the use of blood plasma biomarkers along with Machine Learning concepts is required for accurate, cost-effective, reliable, and accessible methods of AD detection.

## References

- [1] Quitterer, U., & AbdAlla, S. (2020). Improvements of symptoms of Alzheimer's disease by inhibition of the angiotensin system. *Pharmacological research*, 154, 104230.
- [2] Rabbito, A., Dulewicz, M., Kulczyńska-Przybik, A., & Mroczko, B. (2020). Biochemical markers in Alzheimer's disease. *International journal of molecular sciences*, 21(6), 1989.
- [3] Liu, L., Zhao, S., Chen, H., & Wang, A. (2020). A new machine learning method for identifying Alzheimer's disease. *Simulation Modelling Practice and Theory*, 99, 102023.
- [4] O'Bryant, S. E., Xiao, G., Barber, R., Reisch, J., Doody, R., Fairchild, T., ...& Texas Alzheimer's Research Consortium. (2010). A serum protein-based algorithm for the detection of Alzheimer disease. *Archives of neurology*, 67(9), 1077-1081.

- [5] Jiang, Y., Zhou, X., Ip, F. C., Chan, P., Chen, Y., Lai, N. C., ...&Ip, N. Y. (2021). Large-scale plasma proteomic profiling identifies a high-performance biomarker panel for Alzheimer's disease screening and staging. *Alzheimer's & Dementia*.
- [6] O'Bryant, S. E., Xiao, G., Barber, R., Reisch, J., Hall, J., Cullum, C. M., ...& Diaz-Arrastia, R. (2011). A blood-based algorithm for the detection of Alzheimer's disease. *Dementia and geriatric cognitive disorders*, 32(1), 55-62.
- [7] O'Bryant, S. E., Xiao, G., Barber, R., Huebinger, R., Wilhelmsen, K., Edwards, M., ...& Alzheimer's Disease Neuroimaging Initiative. (2011). A blood-based screening tool for Alzheimer's disease that spans serum and plasma: findings from TARC and ADNI. *PloS one*, 6(12), e28092.
- [8] Lee, J. C., Kim, S. J., Hong, S., & Kim, Y. (2019). Diagnosis of Alzheimer's disease utilizing amyloid and tau as fluid biomarkers. *Experimental & molecular medicine*, 51(5), 1-10.
- [9] Zetterberg, H., & Burnham, S. C. (2019). Blood-based molecular biomarkers for Alzheimer's disease. *Molecular brain*, 12(1), 1-7.
- [10] Ashton, N. J., Nevado-Holgado, A. J., Barber, I. S., Lynham, S., Gupta, V., Chatterjee, P.&Hye, A. (2019). A plasma protein classifier for predicting amyloid burden for preclinical Alzheimer's disease. *Science advances*, 5(2), eaau7220.
- [11] Hye, A., Lynham, S., Thambisetty, M., Causevic, M., Campbell, J., Byers, H. L., & Lovestone, S. (2006). Proteome-based plasma biomarkers for Alzheimer's disease. *Brain*, 129(11), 3042-3050.
- [12] Kiddle, S. J., Steves, C. J., Mehta, M., Simmons, A., Xu, X., Newhouse, S., ... & Dobson, R. J. B. (2015). Plasma protein biomarkers of Alzheimer's disease endophenotypes in asymptomatic older twins: early cognitive decline and regional brain volumes. *Translational psychiatry*, 5(6), e584-e584.
- [13] Schilling, L. P., Zimmer, E. R., Shin, M., Leuzy, A., Pascoal, T. A., Benedet, A. L., ...& Rosa-Neto, P. (2016). Imaging Alzheimer's disease pathophysiology with PET. *Dementia & Neuropsychologia*, 10, 79-90.
- [14] Jo, T., Nho, K., & Saykin, A. J. (2019). Deep learning in Alzheimer's disease: diagnostic classification and prognostic prediction using neuroimaging data. *Frontiers in aging neuroscience*, 11, 220.
- [15] Eke, C. S., Jammeh, E., Li, X., Carroll, C., Pearson, S., & Ifeachor, E. (2020). Early Detection of Alzheimer's Disease with Blood Plasma Proteins Using Support Vector Machines. *IEEE journal of biomedical and health informatics*, 25(1), 218-226
- [16] Nagarathna, C. R., & Kusuma, M. (2021, November). Comparative study of detection and classification of Alzheimer's disease using Hybrid model and CNN. In *2021 International Conference on Disruptive Technologies for Multi-Disciplinary Research and Applications (CENTCON)* (Vol. 1, pp. 43-46). IEEE.

- [17] Gómez Ravetti, M., &Moscato, P. (2008).Identification of a 5-protein biomarker molecular signature for predicting Alzheimer's disease.PloS one, 3(9), e3111.
- [18] Kiddle, S. J., Thambisetty, M., Simmons, A., Riddoch-Contreras, J., Hye, A., Westman, E&Alzheimers Disease Neuroimaging Initiative. (2012). Plasma based markers of [11C] PiB-PET brain amyloid burden.
- [19] HT Gorji - Biomarkers Selection Toward Early Detection of Alzheimer's Disease 2020;
- [20] Alzheimer's Dataset ( 4 class of Images) | Kaggle
- [21] ADNI | Alzheimer's Disease Neuroimaging Initiative (usc.edu)
- [22] Alzheimer's Disease and Healthy Aging Data - CKAN